Amgen's US Sensipar patents upheld by a district court

The patents on Amgen's hyperparathyroidism condition treatment, Sensipar (cinacalcet HCl), have been upheld in a US district court, dampening an effort by Teva Pharmaceutical Industries to come to market before patent expiry. Amgen claims that the latest US Sensipar expiry is in 2018. The ruling may be subject to appeal.